Detail of "35838-58-5"

Reference

Influence of cyclic nucleotides and a phosphodiesterase inhibitor on in vitro human blood neutrophil chemotaxis

Influence of cyclic nucleotides and a phosphodiesterase inhibitor on in vitro human blood neutrophil chemotaxis. Rivkin, I.; Neutze, J. A. (Dep. Pharmacol., Squibb Inst. Med. Res., Princeton, N. J., USA). Arch. Int. Pharmacodyn. Ther., 228(2), 196-204 (English) 1977. CODEN: AIPTAK. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Cyclic AMP (I) [60-92-4] and dibutyryl cyclic AMP [362-74-3] as well as several 8-substituted analogs of cyclic AMP inhibited in vitro human blood neutrophil chemotaxis. Cyclic GMP [7665-99-8] enhanced chemotaxis. 8-Substitution on the cyclic GMP nucleus markedly dampened the cyclic GMP effect. SQ 20,009 [35838-58-5], a potent phosphodiesterase inhibitor when tested alone, inhibited chemotaxis; it potentiated the inhibition or enhancement of chemotaxis when combined with I or cyclic GMP, resp.

Hydrolysis and subsequent cyclization of etazolate hydrochloride and related compounds in aqueous solutions: application of PMR and mass spectrometry in accelerated stability studies

Hydrolysis and subsequent cyclization of etazolate hydrochloride and related compounds in aqueous solutions: application of PMR and mass spectrometry in accelerated stability studies.There are some reagents like 35838-58-5 is used in this study. Puar, Mohindar S.; Funke, Phillip T.; Cohen, Allen I. (Squibb Inst. Med. Res., Princeton, N. J., USA). J. Pharm. Sci., 67(6), 850-3 (English) 1978. CODEN: JPMSAE. ISSN: 0022-3549. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 22 The hydrolysis of etazolate-HCl (I) [35838-58-5], an inhibitor of cyclic nucleotide 3',5'-monophosphate phosphodiesterase that degrades cyclic adenosine 3',5'-monophosphate (cyclic AMP) to AMP, and related compds. was studied by PMR and mass spectrometry. The compds. underwent reversible acid-catalyzed hydrolysis in aq. solns. at 60°, followed by cyclization to a major and a minor product formed by independent pathways. Under the exptl. conditions, the minor product was stable. The formation rate of the major product 6-ethyl-1,6-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(2H)ione (II) [37649-55-1], was considerably greater than that of the minor component, 3-ethoxy-6-ethyl-1,6-dihydrodipyrazolo[3,4-b:3',4'-d]pyridine (III) [51700-83-5]. 35838-58-5 is the cas registry number of certain chemical which is used as reagents here. For the 6-Me analog (IV) [67324-49-6] of etazolate, the rate of Me deuteration was considerably slower than the rate of cyclization. ..